Switzer TV

 

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

With tech stocks sold off, resources rotating back into favour, and AI fears dominating headlines, each guest lays out what they’d actually buy now and why.

Adam Dawes kicks things off by explaining why selective commodities, developers and beaten-up growth names are back on the radar, and where investors need to be careful.

Jun Bei Liu then shares her “buy low” Christmas gift ideas, focusing on high-quality growth companies that have fallen out of favour but continue to grow earnings. Finally, Paul Rickard wraps up the year with a pragmatic take on oversold tech, patience, and which names could reward investors willing to look past short-term fear.

Interview timecodes:

00:01:01 - Adam Dawes, Shaw and Partners

00:17:41 - Jun Bei Liu, TenCap

00:25:37 - Paul Rickard, Switzer Report

 

This is our last show for 2025. We thank you for joining us and we'll see you on 10 January, 2026 with a new year of Switzer Investing TV.

Switzer Investing TV (15/12/25): What would our experts invest in now for growth in 2026?

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

More videos

TOP STOCKS from reporting season! + Why these areas for property are looking attractive!

Peter Switzer is joined by ST Wong of Prime Value, CFO of BHP, David Lamont, and Margaret Lomas of Destiny Financial Solutions.

Series:
Mad about Money

Peter Switzer and Paul Rickard share their thoughts on the major current affairs impacting financial markets and the economy.

Series:
The star stocks from reporting season: Telstra, BlueScope, Lovisa + 10 tech stocks analysts love!

Peter Switzer is joined by Michael Wayne of Medallion Financial Group, Adam Dawes of Shaw and Partners, and Paul Rickard from the Switzer Report.

Series:
What is the immune system and what exactly does it do? | The Check Up

In this week's episode, Dr Ross tells us what exactly the immune system is and how it works.

Series:
Is it buy time for stocks with US inflation better than expected? + Stocks in focus: BHP, REA, XRO!

Peter Switzer is joined by Marcus Bogdan of Blackmore Capital, Paul Rickard from the Switzer Report, and senior economist at REA Group, Eleanor Creagh.

Series:
Mad about Money

Peter Switzer and Paul Rickard share their thoughts on the major current affairs impacting financial markets and the economy.

Series:
Is the stock market poised to boom or slump? + We rate these stocks: REA, AD8, BHP & more!

Peter Switzer is joined by Jun Bei Liu of Tribeca Alpha Plus, Michael Gable of Fairmont Equities, and Paul Rickard from the Switzer Report.

Series:
Why it's important to have a healthy immune system | The Check Up

Dr Ross discusses the importance on having a healthy immune system, especially if you contract COVID-19.

Series:
Is it time to have the guts to buy stocks? + Can't buy where you want to live? Try rentvesting!

Peter Switzer is joined by Anna Porter of Suburbanite, Paul Rickard discusses what's ahead for the August reporting season and is joined by Lloyd Edge of Aus Property Professionals.

Series:
Mad about Money

Peter Switzer and Paul Rickard share their thoughts on the major current affairs impacting financial markets and the economy.

Series:
Is EML worth gambling on with a new CEO? Zip and Megaport on a rebound? + ELMO's FY22 results!

Paul Rickard is joined by Adam Dawes of Shaw and Partners, Raymond Chan of Morgans, and Peter Switzer speaks with CFO of ELMO Software, James Haslam.

Series:
Why taking Vitamin D is so beneficial for our bodies | The Check Up

Dr Ross discusses how beneficial taking two capsules of Vitamin D a day is, with studies showing a 22% reduction in common autoimmune diseases.

Series:
1 11 12 13 14 15 51

Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox

Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
Subscribe
© 2006-2021 Switzer. All Rights Reserved. Australian Financial Services Licence Number 286531. 
shopping-cartphoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram